Greg Keenan's most recent trade in Aurinia Pharmaceuticals Inc was a trade of 8,305 Common Stock done at an average price of $8.2 . Disclosure was reported to the exchange on March 7, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Aurinia Pharmaceuticals Inc | Greg Keenan | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 8.23 per share. | 07 Mar 2025 | 8,305 | 153,484 (0%) | 0% | 8.2 | 68,350 | Common Stock |
Aurinia Pharmaceuticals Inc | Greg Keenan | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 95,570 | 95,570 | - | - | Employee Stock Option (right to buy) | |
Aurinia Pharmaceuticals Inc | Greg Keenan | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 62,583 | 174,028 (0%) | 0% | 0 | Common Stock | |
Aurinia Pharmaceuticals Inc | Greg Keenan | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 8.00 per share. | 28 Feb 2025 | 12,239 | 161,789 (0%) | 0% | 8 | 97,912 | Common Stock |